Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03670316 · ClinicalTrials.gov registry record · Phase 4
Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 371
- Enrollment target
NCT03670316 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 371 participants.
The verdict
NCT03670316, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 371 participants
- Enrollment target
Study Summary
To determine the efficacy of an algorithm designed to recommend smoking cessation-related pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS.
Interventions
- DRUG Algorithm Treatment
- OTHER Quitline only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 371 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03670316
The ClinicalTrials.gov registry entry for NCT03670316 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 371 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Algorithm Treatment is the first listed.
NCT03670316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03670316 about?
NCT03670316 is a clinical study titled "Effectiveness of a Smoking Cessation Algorithm Integrated Into HIV Primary Care". To determine the efficacy of an algorithm designed to recommend smoking cessation-related pharmacotherapy options to the primary care providers of smokers living with HIV/AIDS.
What is the current status of trial NCT03670316?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 371 participants. The study started on 2020-08-17. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT03670316?
The interventions under investigation include: Algorithm Treatment (DRUG), Quitline only (OTHER).
Who is sponsoring clinical trial NCT03670316?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.